Nanomedicine prompts RNA to make protein-based drugs to treat diseases. Now we can fine-tune protein production by dialling ...

Once the most successful mRNA-based LNP was tested in 3D in vitro models, the fluorescent dye continued to facilitate ...

Nucleic acid-based therapeutics, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA), hold ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

The mRNA therapeutics industry faces a critical manufacturing challenge that threatens both product safety and commercial viability. Double-stranded RNA (dsRNA) formation during in vitro transcription ...

Advances in mRNA design continue to shape the next generation of therapeutic development. Yet, achieving strong and sustained protein expression remains a persistent challenge across platforms.

Researchers develop a self-regulating mRNA medicine that adjusts protein production based on disease-related signals. A research team from The University of Osaka and Institute of Science Tokyo has ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

Recent trends in cancer distribution and survival outcomes among adolescent and young adult patients: A national data analysis.